Dual chamber prefilled syringes are extensively used in infusion therapy for dual purposes intravenous drug administration and flushing chambers. Existing patents allow for only sequential use. Evolving standards of care in infusion therapy have paved way for continuous design advances in vascular access device (VAD), with the safety and efficacy of dual chamber prefilled syringes garnering attention. Growing use of peripheral intravenous catheter (PIVC) in infusion therapy for administering drugs and blood products is a key trend bolstering the expansion opportunities for manufacturers in dual chamber prefilled syringes market. Key forms are liquid/liquid and liquid/powder. Key focus of manufacturers is to manage common catheter-related complications, reduce contamination risks, and also reduce procedural times. Expanding patents has led to improvements in the safety of dual chamber prefilled syringes.
Dual chamber prefilled syringes are used in a wide range of indications some of which are hemophilia, schizophrenia, endometriosis, erectile dysfunction, and diabetes. The study on the dual chamber prefilled syringes market makes a critical analysis of major product developments, research avenues, degree of concentration of key players, key forces of market, and supply and demand analysis. The various insights offer assessment of market opportunities in various end-use segments and their shares in the global dual chamber prefilled syringes market.
The drive for improving the outcomes of intravenous therapeutics and flushing in infusion therapy is a key trend boosting the growth of the dual chamber prefilled syringes market. Over the past years, there has been substantial rise in number of patients with PIVC experiencing catheter-related complications, phlebitis, and bloodstream infections. Updating of guidelines and standards of care have helped in the evolution of the dual chamber prefilled syringes market. However, the rate of launch of such syringes is relatively low. Particularly, industry players are expected to benefit from the need to develop syringes that allow sequential use of the flushing chamber for pre- and post-intravenous procedure.
Also, the literature lacks due to which there is lack of definite information to healthcare professionals and providers. Further, there is an urgent need for making the technology cost-effective for adoption. Nevertheless, strides made in biopharmaceutical industry are bolstering the growth of the dual chamber prefilled syringes market.
A number of clinical studies have been done with an aim to test the advantage of dula chamber prefilled syringes over classic syringes in peripheral intravenous drug administration and catheter flushing. One such study was performed by researchers from Portugal. As many 146 adult patients were part of multi-center, two-arm randomized controlled trials. The aim of the study was to develop guidelines for nurses handling intravenous procedures. The effectiveness and safety was thoroughly tested. The incidence of nosocomial bacteraemia in PIVC was one of the several catheter-related complications that were tested. Such studies will help develop inexpensive devices in the dual chamber prefilled syringes. A number of manufacturers are testing new materials in the making of the syringes, most prominent of which is glass.
Some of the key regions in the dual chamber prefilled syringes market are North America, Asia, and Europe. North America and Europe are promising markets. A large part of the demand comes from clinical role of these syringes in managing patients with hemophilia. North America has been a substantially lucrative market, with manufacturers expanding their production capacities. Rise in awareness about catheter-related infections in the healthcare systems in Asia is also fueling the avenues for manufacturers in the dual chamber prefilled syringes market.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.